Evidence map›Paper›PMID 37652904›Full record

ArticleNature communications2023

Portosystemic shunt placement reveals blood signatures for the development of hepatic encephalopathy through mass spectrometry.

Ana Carolina Dantas Machado, Stephany Flores Ramos, Julia M Gauglitz, Anne-Marie Fassler, Daniel Petras, Alexander A Aksenov, Un Bi Kim, Michael Lazarowicz, Abbey Barnard Giustini, Hamed Aryafar and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Ana Carolina Dantas Machado *Division of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA, USA.
Stephany Flores Ramos *Division of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-1918-9769
Julia M GauglitzSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.
Anne-Marie FasslerDepartment of Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.
Daniel PetrasSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6561-3022
Alexander A AksenovSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.
Un Bi KimDepartment of Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.
Michael LazarowiczDepartment of Radiology, Division of Interventional Radiology, College of Medicine, University of Florida, Gainesville, FL, USA.
Abbey Barnard GiustiniDivision of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA, USA.
Hamed AryafarSan Diego Imaging, San Diego, CA, USA.
Irine VodkinDivision of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA, USA.
Curtis WarrenDepartment of Surgery, College of Medicine, University of Florida, Gainesville, FL, USA.
Pieter C DorresteinSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3003-1030
Ali ZarrinparDepartment of Surgery, College of Medicine, University of Florida, Gainesville, FL, USA. ali.zarrinpar@surgery.ufl.edu.
Amir ZarrinparDivision of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA, USA. azarrinpar@ucsd.edu.ORCID http://orcid.org/0000-0001-6423-5982
University of California San Diego · USUniversity of Florida · USVeterans Health Administration · USUniversity of California San Diego Medical Center · USUniversity of Connecticut · USUniversity of Washington · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Ye Zheng · 1985 to 2026
$82.8M
The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8M
The Role of Altered Luminal Dynamics in OSA-Induced AtherosclerosisR01HL148801 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZARRINPAR, AMIR · 2019 to 2023
$4.0M
UC San Diego Clinical and Translational Research InstituteTL1TR001443 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2019
$3.4M
Engineering Native E. coli to Detect, Report, and Treat Colorectal CancerU01CA265719 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZARRINPAR, AMIR · 2021 to 2025
$3.1M
Development of Engineered Native Bacteria as a Tool for Functional Manipulation of the Gut MicrobiomeR01AI163483 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEFF M HASTY, Amir Zarrinpar · 2023 to 2026
$3.1M
Design and characterization of bacterial population dynamics in solid tumor modelsR01EB030134 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HASTY, JEFF M, TSIMRING, LEV S · 2021 to 2024
$2.5M
Ischemia-reperfusion injury in liver transplantationK08DK113244 · NIDDK · UNIVERSITY OF FLORIDA · PI ZARRINPAR, ALI · 2017 to 2021
$814k
The Relationship of Gut Microbiome and Time Restricted Feeding in MetabolismK08DK102902 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZARRINPAR, AMIR · 2015 to 2019
$789k
BLRD VA I01 BX005707NCATS NIH HHS TL1 TR001443NCATS NIH HHS UL1 TR001442NCI NIH HHS P30 CA014195NCI NIH HHS U01 CA265719NHLBI NIH HHS R01 HL148801NIAAA NIH HHS P50 AA011999NIBIB NIH HHS R01 EB030134NIDDK NIH HHS K08 DK102902NIDDK NIH HHS K08 DK113244NIDDK NIH HHS P30 DK063491NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R03 DK114536NIMH NIH HHS R21 MH117780
6 · The paper itself

Abstract

Elective transjugular intrahepatic portosystemic shunt (TIPS) placement can worsen cognitive dysfunction in hepatic encephalopathy (HE) patients due to toxins, including possible microbial metabolites, entering the systemic circulation. We conducted untargeted metabolomics on a prospective cohort of 22 patients with cirrhosis undergoing elective TIPS placement and followed them up to one year post TIPS for HE development. Here we suggest that pre-existing intrahepatic shunting predicts HE severity post-TIPS. Bile acid levels decrease in the peripheral vein post-TIPS, and the abundances of three specific conjugated di- and tri-hydroxylated bile acids are inversely correlated with HE grade. Bilirubins and glycerophosphocholines undergo chemical modifications pre- to post-TIPS and based on HE grade. Our results suggest that TIPS-induced metabolome changes can impact HE development, and that pre-existing intrahepatic shunting could be used to predict HE severity post-TIPS.

Indexed as

Hepatic EncephalopathyPortasystemic Shunt, Transjugular IntrahepaticBile Acids and SaltsHumansMass SpectrometryProspective StudiesVeinsBile Acids and Salts

Identifiers

PMID37652904
PMCPMC10471626
OpenAlexW4386316883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.